A recent study revealed that patients with HS have a 23% prevalence of IA, emphasizing the need for routine screening in dermatologic practice.

Christophe Bourdon, CEO, discusses LEO Pharma's groundbreaking presentations at EADV, delgocitinib's US pending approval, and the company's commitment to addressing chronic hand eczema.

Lio addresses one of the NEA's Eczema Awareness Month weekly themes, "What is eczema?"

Song stressed the need for careful therapy selection in patients with comorbid conditions to avoid exacerbating health issues.

In case you missed it, this week we had news about delgocitinib's launch in Germany, the FDA clearance of Accure's laser system for long-term acne treatment, BE BOLD study highlights, and more.

The multicenter trial reported high response rates and low risk of discontinuation for treating long-term chronic inducible urticaria.

Historically, research and clinical practice often have overlooked the distinct manifestations and treatment needs of patients with skin of color who have psoriasis.

This represents the second approval of Zoryve outside the US.

The case series found dupilumab led to improvements in skin condition and a reduction in bacterial infections for pediatric patients with Hyper-IgE syndrome.

Forlenza addresses one of the NEA's Eczema Awareness Month weekly themes, "Tools for living your most ecz-pressive life with eczema."

In a Dermatology Times Case-Based Roundtable event, James Del Rosso, DO, shared pearls for challenging acne cases.

With this combined administration, patients saw noticeable and lasting improvements in severe cases of AD.

Studies show conflicting serum levels of zinc and copper in vitiligo patients, indicating a need for further research.

The study represents the first to evaluate health care resource utilization among individuals with PN in England.

Developed by a panel of global dermatology experts, the SQS addresses the multifaceted nature of skin quality.

In this month's Cosmetic Conundrums column, explore 4 eyelash growth scenarios.

Results from Society for Melanoma Research Congress demonstrated excellent predictive power of noninvasive CP-GEP Merlin test.

Although further research is still needed, dermatologists and patients are generally satisfied with teledermatology treatment.

The app demonstrated high sensitivity (92.0%) and specificity (95.5%) in identifying skin changes through a controlled testing environment.

Along with this new transparency regarding treatments, patients are empowered to embrace more comprehensive beauty ideals.

In a Dermatology Times Case-Based Roundtable event, Chesahna Kindred, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib cream.

The new delivery systems for bimekizumab-bkzx represent an upgrade over previous 1 mL options, reducing the frequency of injections required.

Robb delved into how the system is transforming skin treatments with advanced precision, faster results, and improved patient outcomes.

The study design emphasizes elevated endpoints, particularly joint health, ensuring that the most relevant outcomes are prioritized for patient care.